drug
FULVESTRANT
Marketedupdated 3mo agoby Eagle Pharmaceuticals Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2all catalysts(4)
Trials studying FULVESTRANT
- phase1A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer
- phase2ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors
- phase1A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
- phase1Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
- phase1A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
- phase2Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- phase2A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
- phase3Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 14, 2034
~7.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- May 17, 2034formulationUS 9271990
- Feb 14, 2034formulationUS 10188663
- Feb 14, 2034formulationUS 9833459
News(10)
- Celcuity gains FDA approval for closely watched breast cancer drugStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.biopharma_dive · 27d ago
- Celcuity wins approval for breast cancer drug RevtorpykA small public biotech won approval for a breast cancer drug that was designed to improve on similar treatments from Novartis and Roche. The FDA on Tuesday cleared Celcuity's Revtorpyk in combinati…endpoints · 27d ago
- Evolving Oral SERD Research Seeks to Redefine Treatment Strategies in Hormone Receptor+ Breast CancerBreast cancer experts discuss the nuances of ESR1 mutations and oral SERD use in hormone receptor–positive breast cancer.onclive · 2mo ago
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 3mo ago
- Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie BondDr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.onclive · 3mo ago
- Dr Silbermann on Clinical Trial Design Considerations in Multiple MyelomaRebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.onclive · 3mo ago
- MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine TumorsRoswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.onclive · 3mo ago
- Dr Randall on the Rationale for Investigating CSF-1R Inhibition in TGCTR. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.onclive · 3mo ago
- Renal Cell Carcinoma: Real-World Factors in First-Line Treatment SelectionIn this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged discuss how real-world patient factors influence first-line treatment decisions in renal cell carcinoma.onclive · 3mo ago
- Expanding ctDNA Applications to RCC and Germ Cell TumorsExperts explain how ctDNA tracking in metastatic cancer guides therapy tweaks, flags relapse early, and where it fails in brain/peritoneal disease.onclive · 3mo ago
Data sources
last refreshed 50m ago
Found something off?
comments(0)
5-min edit window · permanent after that